Question: is ilumya covered by medicare?
Answer: Ilumya (tildrakizumab) is an interleukin-23 antagonist indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Medicare does not have a National Coverage Determination (NCD) for ILUMYA™ (tildrakizumab-asmn) injections.